As such the search for novel, non-toxic insulin mimetics which selectively activate INSR continues and is becoming increasingly urgent as insulin costs continue to rise beyond the realm of affordability for many diabetics [18–20] (http://www.cbsnews.com/news/the-rising-cost-of-insulin-horror-stories-every-day/, http://www.nytimes.com/2018/06/22/well/diabetes-patients-at-risk-from-rising-insulin-prices.html). This evidence concerns the gene INS and diabetes mellitus.